Drug intelligence / Profile preview

ORK-1

Development stage: Preclinical
Lead developer: Orikine Bio
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

ORK-1 is a first-in-class bi-specific cytokine developed by Orikine Bio using its proprietary Foldikine platform. It is designed to reprogram macrophages to treat Th1-mediated inflammatory conditions. The drug is engineered to deliver dual signals to specific immune cells, allowing for precise control of the immune response. ORK-1 is currently the lead program for Orikine Bio, targeting Inflammatory Bowel Disease (including Crohn's disease and ulcerative colitis) and rheumatoid arthritis. It is in the preclinical stage, with IND-enabling studies planned for 2025.

Beyond the preview

Go deeper on ORK-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORK-1.

Explore the full profile